Related references
Note: Only part of the references are listed.Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways
Joseph Yi Zhou et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
K. Cusi et al.
DIABETIC MEDICINE (2018)
Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet
Wei Zhu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Liraglutide modulates gut microbiota and reduces NAFLD in obese mice
G. V. Moreira et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2018)
Glycemic Targets: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Lifestyle Management: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial
Mark M. Smits et al.
DIABETES CARE (2017)
Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study
Jean-Michel Petit et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial
Ryotaro Bouchi et al.
ENDOCRINE JOURNAL (2017)
GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway
Qin He et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
Mark M. Smits et al.
DIABETOLOGIA (2016)
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Jeffrey Cui et al.
JOURNAL OF HEPATOLOGY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Zhixia Li et al.
PLOS ONE (2016)
Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
An Tang et al.
DIABETES CARE (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial)
Rohit Loomba et al.
HEPATOLOGY (2015)
Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up
Mattias Ekstedt et al.
HEPATOLOGY (2015)
Fatty Pancreas, Insulin Resistance, and β-Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging
Vincent Wai-Sun Wong et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Exendin-4, a glucagon-like peptide-1 receptor agonist, modulates hepatic fatty acid composition and Δ-5-desaturase index in a murine model of non-alcoholic steatohepatitis
Takumi Kawaguchi et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2014)
Association of Pancreatic Fatty Infiltration With Pancreatic Ductal Adenocarcinoma
Mika Hori et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2014)
Use of AUDIT-Based Measures to Identify Unhealthy Alcohol Use and Alcohol Dependence in Primary Care: A Validation Study
J. Aaron Johnson et al.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2013)
Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease
N. S. Patel et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Association between non-alcoholic fatty pancreatic disease (nafpd) and the metabolic syndrome: case-control retrospective study
Wan-Chen Wu et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Emerging Quantitative Magnetic Resonance Imaging Biomarkers of Hepatic Steatosis
Scott B. Reeder
HEPATOLOGY (2013)
Utility of Magnetic Resonance Imaging Versus Histology for Quantifying Changes in Liver Fat in Nonalcoholic Fatty Liver Disease Trials
Mazen Noureddin et al.
HEPATOLOGY (2013)
Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet
Jamie E. Mells et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
James L. Trevaskis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice
Jinmi Lee et al.
PLOS ONE (2012)
Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents The TONIC Randomized Controlled Trial
Joel E. Lavine et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
Shvetank Sharma et al.
PLOS ONE (2011)
Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c
P. Ferre et al.
DIABETES OBESITY & METABOLISM (2010)
Clinical implications of fatty pancreas: Correlations between fatty pancreas and metabolic syndrome
Jun Seok Lee et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
XK Ding et al.
HEPATOLOGY (2006)
Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome
SG Mattar et al.
ANNALS OF SURGERY (2005)
Obesity, recreational physical activity, and risk of pancreatic cancer in a large US cohort
AV Patel et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
Medical progress - Nonalcoholic fatty liver disease
P Angulo
NEW ENGLAND JOURNAL OF MEDICINE (2002)
A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver
H Yamashita et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
